4556 — Kainos Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMicro CapSuper Stock

Annual income statement for Kainos Laboratories, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4,258	4,615	4,923	5,056	5,306
Cost of Revenue
Gross Profit	2,311	2,407	2,513	2,552	2,674
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,667	3,873	4,111	4,202	4,483
Operating Profit	591	742	812	854	822
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	613	767	845	930	827
Provision for Income Taxes
Net Income After Taxes	417	512	568	638	641
Net Income Before Extraordinary Items
Net Income	417	512	568	638	641
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	417	512	568	638	641
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	107	128	138	153	152
Dividends per Share
Special Dividends per Share